Talmadge E. King Jr, MD
Dean-SOM/VC-Medical Affairs
Dean's Office
School of Medicine

From 2006 to 2015, he served as chair of the UCSF Department of Medicine, the largest department in the school, with approximately 29 percent of the school's full-time faculty.

A physician-scientist, King’s research has focused on inflammatory and immunologic lung injury. He is best known for his pioneering work in the management of the interstitial pneumonias, a scarring process that often leads to death. His bibliography comprises more than 300 publications and he has co-edited eight books, including the acclaimed reference book, "Interstitial Lung Disease," now in its fifth edition.

King graduated from Gustavus Adolphus College and earned his medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga. and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver.

He is a member of the Institute of Medicine of the National Academy of Sciences, American Academy of Arts and Sciences, Association of American Physicians, American Clinical and Climatological Association and the Fleischner Society. He is a master of the American College of Physicians and fellow of the American College of Chest Physicians. He won the 2007 Trudeau Medal, the highest honor of the American Thoracic Society.

• The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
  Respiratory medicine 2017 Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE, Kim DS, Collard HR, Lee JS
• The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.
  Thorax 2017 Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE, Wolters PJ, Collard HR, Ley B
• Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.
  Academic medicine : journal of the Association of American Medical Colleges 2017 Sehgal NL, Neeman N, King TE
• A diagnostic model for chronic hypersensitivity pneumonitis.
  Thorax 2016 Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Wolters PJ, Collard HR
• Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
  Thorax 2016 Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, …
• Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.
  BMJ open respiratory research 2016 Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW
• Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
  The European respiratory journal 2015 Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE
• American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.
  Radiographics : a review publication of the Radiological Society of North America, Inc 2015 Sverzellati N, Lynch DA, Hansell DM, Johkoh T, King TE, Travis WD
• Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.
  Respiratory medicine 2015 Assayag D, Kim EJ, Elicker BM, Jones KD, Golden JA, King TE, Koth LL, Shum AK, Wolters PJ, Collard HR, Lee JS
• Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.
  Chest 2015 Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW
• The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.
  Respiratory medicine 2015 Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR
• CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.
  The Lancet. Respiratory medicine 2015 Hansell DM, Goldin JG, King TE, Lynch DA, Richeldi L, Wells AU
• Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
  Respiratory medicine 2015 Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE
• A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.
  The European respiratory journal 2015 Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK
• Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
  The Lancet. Respiratory medicine 2015 Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ, IPFnet investigators
• Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
  Respirology (Carlton, Vic.) 2015 Moodley Y, Corte T, Richeldi L, King TE
• Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
  Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2014 Costabel U, Albera C, Bradford WZ, Hormel P, King TE, Noble PW, Sahn SA, Valeyre D, du Bois RM
• Treatments for idiopathic pulmonary fibrosis.
  The New England journal of medicine 2014 King TE, Noble PW, Bradford WZ
• Smoking-related idiopathic interstitial pneumonia.
  The European respiratory journal 2014 Flaherty KR, Fell C, Aubry MC, Brown K, Colby T, Costabel U, Franks TJ, Gross BH, Hansell DM, Kazerooni E, Kim DS, King TE, Kitachi M, Lynch D, Myers J, Nagai S, Nicholson AG, Poletti V, Raghu G, …
• Idiopathic pulmonary fibrosis: CT and risk of death.
  Radiology 2014 Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE, Collard HR
• A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
  The New England journal of medicine 2014 King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble …
• Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
  Respirology (Carlton, Vic.) 2014 Valeyre D, Albera C, Bradford WZ, Costabel U, King TE, Leff JA, Noble PW, Sahn SA, du Bois RM
• Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
  The New England journal of medicine 2014 Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE, Raghu G
• All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
  American journal of respiratory and critical care medicine 2014 King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW
• Predicting survival across chronic interstitial lung disease: the ILD-GAP model.
  Chest 2014 Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Collard HR
• Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.
  American journal of respiratory and critical care medicine 2014 Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty …
• Rheumatoid arthritis associated interstitial lung disease: a review.
  Medicina 2014 Assayag D, Lee JS, King TE
• Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.
  Respirology (Carlton, Vic.) 2013 Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ
• Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.
  Respiratory medicine 2013 Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS, IPFnet Investigators
• 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.
  The European respiratory journal 2013 du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE
• Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.
  Radiology 2013 Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS
• An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
  American journal of respiratory and critical care medicine 2013 Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M…
• Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.
  Chest 2013 Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen MLT, Woodruff PG, Jones KD, Collard HR, King TE, Koth LL
• Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.
  Respiratory research 2013 Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, IPFnet investigators
• Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.
  Chest 2013 Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR
• Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.
  The Lancet. Respiratory medicine 2013 Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G, IPFnet Investigators
• Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.
  American journal of respiratory and critical care medicine 2013 Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK
• Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.
  Chest 2013 Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ, IPFnet Investigators
• Prevalence and prognosis of unclassifiable interstitial lung disease.
  The European respiratory journal 2012 Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Wolters PJ, Collard HR
• Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.
  Respiratory medicine 2012 Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Collard HR
• Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.
  American journal of respiratory and critical care medicine 2012 Selman M, Pardo A, King TE
• Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
  The New England journal of medicine 2012 Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ
• A multidimensional index and staging system for idiopathic pulmonary fibrosis.
  Annals of internal medicine 2012 Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR
• A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.
  American journal of respiratory and critical care medicine 2012 Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA, Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet)
• Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.
  American journal of respiratory and critical care medicine 2012 Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK
• Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.
  Thorax 2012 Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR
• Interstitial lung diseases. Preface.
  Clinics in chest medicine 2012 King TE, Collard HR, Richeldi L
• Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
  American journal of respiratory and critical care medicine 2011 du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU
• Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.
  American journal of respiratory and critical care medicine 2011 du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE
• Idiopathic pulmonary fibrosis.
  Lancet (London, England) 2011 King TE, Pardo A, Selman M
• Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.
  American journal of respiratory and critical care medicine 2011 Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR
• Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
  Lancet (London, England) 2011 Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, CAPACITY Study Group
• BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
  American journal of respiratory and critical care medicine 2011 King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J
• An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
  American journal of respiratory and critical care medicine 2011 Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M,…
• Smoking and subclinical interstitial lung disease.
  The New England journal of medicine 2011 King TE
• Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
  American journal of respiratory and critical care medicine 2010 du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE
• Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
  American journal of respiratory and critical care medicine 2010 Ley B, Collard HR, King TE
• Workshop on idiopathic pulmonary fibrosis in older adults.
  Chest 2010 Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, King TE, Horne FM, Nayfield SG, Reynolds HY, Schmader KE, Toews GB, High KP
• Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.
  Journal of occupational and environmental medicine 2010 Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE, Harber P, Balmes JR
• Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.
  American journal of physiology. Lung cellular and molecular physiology 2010 Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, Kim DS
• Does chronic microaspiration cause idiopathic pulmonary fibrosis?
  The American journal of medicine 2010 Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE
• Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.
  Lung 2010 Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE
• Clinical decisions. American Board of Internal Medicine maintenance of certification program.
  The New England journal of medicine 2010 Levinson W, King TE, Goldman L, Goroll AH, Kessler B
• The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.
  Thorax 2009 Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK
• Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.
  Chest 2009 Kim EJ, Collard HR, King TE
• The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.
  Respiratory medicine 2009 Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS
• Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.
  American journal of respiratory and critical care medicine 2009 Buckley JD, Addrizzo-Harris DJ, Clay AS, Curtis JR, Kotloff RM, Lorin SM, Murin S, Sessler CN, Rogers PL, Rosen MJ, Spevetz A, King TE, Malhotra A, Parsons PE
• Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
  Lancet (London, England) 2009 King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM, INSPIRE Study Group
• Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.
  Chest 2009 Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE
• Bosentan for idiopathic pulmonary fibrosis.
  Current opinion in investigational drugs (London, England : 2000) 2008 King TE
• Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.
  American journal of respiratory and critical care medicine 2008 Kinder BW, King TE
• Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.
  American journal of respiratory and critical care medicine 2008 Travis WD, Hunninghake G, King TE, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T…
• Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.
  Chest 2007 Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE
• Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.
  Thorax 2007 du Bois R, King TE
• BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
  American journal of respiratory and critical care medicine 2007 King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G
• Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.
  Respiratory medicine 2007 Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE, Golden JA
• Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.
  Arthritis and rheumatism 2007 Kinder BW, Freemer MM, King TE, Lum RF, Nititham J, Taylor K, Edberg JC, Bridges SL, Criswell LA
• Acute exacerbations of idiopathic pulmonary fibrosis.
  American journal of respiratory and critical care medicine 2007 Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, …
• Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?
  American journal of respiratory and critical care medicine 2007 Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE
• Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.
  Thorax 2007 Gotway MB, Freemer MM, King TE
• Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.
  PloS one 2007 Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, Kaminski N
• Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.
  Respiratory medicine 2007 Collard HR, Loyd JE, King TE, Lancaster LH
• Respiratory bronchiolitis-interstitial lung disease: long-term outcome.
  Chest 2007 Portnoy J, Veraldi KL, Schwarz MI, Cool CD, Curran-Everett D, Cherniack RM, King TE, Brown KK
• Clinical problem-solving. Anchors away.
  The New England journal of medicine 2007 Calfee CS, Shah SJ, Wolters PJ, Saint S, King TE
• Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?
  American journal of respiratory and critical care medicine 2007 Flaherty KR, Andrei AC, King TE, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, Gay SE, Gross BH, Kazerooni EA, Knapp R, Louvar E, Lynch D, Nicholson AG, Quick J, Thannickal VJ, …
• Anticoagulant therapy and idiopathic pulmonary fibrosis.
  Chest 2006 Kinder BW, Collard HR, King TE
• Classification and natural history of the idiopathic interstitial pneumonias.
  Proceedings of the American Thoracic Society 2006 Kim DS, Collard HR, King TE
• Current perspectives on the treatment of idiopathic pulmonary fibrosis.
  Proceedings of the American Thoracic Society 2006 Walter N, Collard HR, King TE
• Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.
  Respiration; international review of thoracic diseases 2006 Perez RL, Kimani AP, King TE, Aguayo SM, Roman J, Emory Interstitial Lung Disease Center
• Achieving diversity in academic internal medicine: recommendations for leaders.
  The American journal of medicine 2006 Wesson DE, King TE, Todd RF, Torres EA, Hellmann DB, Flack JM, Dubose TD, Schuster VL
• A critical assessment of treatment options for idiopathic pulmonary fibrosis.
  Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2005 Shah NR, Noble P, Jackson RM, King TE, Nathan SD, Padilla M, Raghu G, Rhodes MB, Schwarz M, Tino G, Dubois RW
• COPD: a dust-induced disease?
  Chest 2005 Girod CE, King TE
• Idiopathic interstitial pneumonias: CT features.
  Radiology 2005 Lynch DA, Travis WD, Müller NL, Galvin JR, Hansell DM, Grenier PA, King TE
• The clinical course of patients with idiopathic pulmonary fibrosis.
  Annals of internal medicine 2005 Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK, IPF Study Group
• High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.
  American journal of respiratory and critical care medicine 2005 Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE, Bradford WZ, Schwartz DA, Richard Webb W, Idiopathic Pulmonary Fibrosis Study Group
• Clinical advances in the diagnosis and therapy of the interstitial lung diseases.
  American journal of respiratory and critical care medicine 2005 King TE
• Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.
  Chest 2005 King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA
• Inequality in health care: unjust, inhumane, and unattended!
  Annals of internal medicine 2004 King TE, Wheeler MB
• Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?
  American journal of respiratory and critical care medicine 2004 Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ
• Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.
  Chest 2004 Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-Everett D, King TE, Brown KK
• The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.
  The American journal of medicine 2004 Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK
• The case for diversity in academic internal medicine.
  The American journal of medicine 2004 King TE, Dickinson TA, DuBose TD, Flack JM, Hellmann DB, Pamies RJ, Todd RF, Torres EA, Wesson DE
• A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.
  The New England journal of medicine 2004 Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE, Idiopathic Pulmonary Fibrosis Study Group
• Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.
  Transactions of the American Clinical and Climatological Association 2004 King TE
• Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.
  Seminars in respiratory and critical care medicine 2003 King TE
• Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.
  Chest 2003 Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Müller N, Schwartz DA, King TE, Lynch JP, Hegele R, Waldron J, Colby TV, Hogg JC
• Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.
  Chest 2003 Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE
• Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.
  American journal of respiratory and critical care medicine 2003 Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK
• Demystifying idiopathic interstitial pneumonia.
  Archives of internal medicine 2003 Collard HR, King TE
• Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.
  American journal of respiratory and critical care medicine 2002 Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE, Leinwand LA, Liotta L, Martin GR, Schwartz DA, Schultz GS, Wagner CR, Musson RA
• Racial disparities in clinical trials.
  The New England journal of medicine 2002 King TE
• Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.
  Journal of computer assisted tomography 2002 Park JS, Brown KK, Tuder RM, Hale VA, King TE, Lynch DA